Refractory Metastatic Melanoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers And Barriers

(MENAFN- GetNews)

DelveInsight's,
“Refractory Metastatic Melanoma Pipeline Insight 2024”
report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Refractory metastatic melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Refractory Metastatic Melanoma Research. Learn more about our innovative pipeline today! @ Refractory Metastatic Melanoma Pipeline Outlook

Key Takeaways from the Refractory Metastatic Melanoma Pipeline Report

• In October 2024:- Sensei Biotherapeutics Inc.- A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors. Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.
• In October 2024:- MacroGenics- Study CP-MGC018-03 is an open-label, two-part, Phase 2 study. Part 1 of the study will enroll participants with metastatic castration-resistant prostate cancer (mCRPC) previously treated with one prior androgen receptor axis-targeted therapy (ARAT). ARAT includes abiraterone, enzalutamide, or apalutamide. Participants may have received up to 1 prior docetaxel-containing regimen, but no other chemotherapy agents.
• In October 2024:- Georgiamune Inc.- GIM531-CT01 is a Phase 1/2 open label, first-in-human, multicenter study. The Phase 1 portion will include a dose escalation with GIM-531 administered as a single agent. Additionally, there will be a dose expansion portion at the safety-cleared dose levels with participants allocated 1:1 within the proposed therapeutic range to accrue additional data for determining the safety profile, pharmacokinetics (PK) profile, pharmacodynamic (PD) effects and early anti-tumor activity of GIM-531. In Phase 2, GIM-531will be administered to participants with advanced/metastatic cutaneous melanoma who have progressed following treatment with an anti-PD-1 therapy.
• DelveInsight's Renal Cancer pipeline report depicts a robust space with 10+ Refractory Metastatic Melanoma companies working to develop 10+ pipeline therapies for Refractory Metastatic Melanoma treatment.
• The leading Refractory Metastatic Melanoma Companies such as Idera Pharmaceuticals, Bristol-Myers Squibb, Sunesin Pharmaceuticals, Taiga biotechnologies, BioNtech , and others.
• Promising Refractory Metastatic Melanoma Therapies such as GIM-531, BNT111, Pembrolizumab, BA3071, SEA-CD40, SNS-101 (anti-VISTA), Cemiplimab, and others.

Stay informed about the cutting-edge advancements in Refractory Metastatic Melanoma Treatments. Download for updates and be a part of the revolution in cancer care @ Refractory Metastatic Melanoma Clinical Trials Assessment

Refractory metastatic melanoma Emerging Drugs

• IMO-2125: Idera Pharmaceuticals

Idera Pharmaceuticals' new drug candidate, IMO-2125, is an intratumoral injection in development for the treatment of refractory metastatic melanoma from staged II b to IV. The drug has demonstrated good efficacy in its phase I and phase II clinical trials. IMO-2125 is a toll-like receptor agonist that signals the immune system to create and activate cancer-fighting cells (T-cells) to target solid tumors in refractory melanoma patients.

• Linrodostat: Bristol-Myers Squibb

Bristol's“breakthrough” drug Linrodostat is an orally administered drug molecule is currently being evaluated for the treatment of refractory metastatic melanoma and has demonstrated good safety and tolerability in Phase I trials. Linrodostat is an inhibitor of indoleamine 2, 3-deoxygenase 1 (IDO1) with potential immunomodulating and antineoplastic activities.

Learn more about Refractory Metastatic Melanoma Drugs opportunities in our groundbreaking Refractory Metastatic Melanoma Research and development projects @ Refractory Metastatic Melanoma Unmet Needs

Refractory metastatic melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Molecule Type

Refractory Metastatic Melanoma Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies
• Product Type

Discover the latest advancements in Refractory Metastatic Melanoma Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Refractory Metastatic Melanoma Market Drivers and Barriers, and Future Perspectives

Scope of the Refractory Metastatic Melanoma Pipeline Report

• Coverage- Global
• Refractory Metastatic Melanoma Companies- Idera Pharmaceuticals, Bristol-Myers Squibb, Sunesin Pharmaceuticals, Taiga biotechnologies, BioNtech, and others.
• Refractory Metastatic Melanoma Therapies- GIM-531, BNT111, Pembrolizumab, BA3071, SEA-CD40, SNS-101 (anti-VISTA), Cemiplimab, and others.
• Refractory Metastatic Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Refractory Metastatic Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Refractory Metastatic Melanoma Pipeline on our website @ Refractory Metastatic Melanoma Drugs and Companies

Table of Content